Clinical medicine (London, England)
-
Acute myeloid leukaemia is a heterogeneous disease that occurs in all age groups but peaks in older age at around a median of 69-70 years where it has a frequency of 13-15/100,00/annum. With the changing demographics, the number of cases will increase in line with the older population. As the only treatment with curative intent is intensive chemotherapy, this presents an immediate therapeutic challenge for the majority of the disease.
-
The number of older substance misusers requiring treatment is likely to double over the next couple of decades. However, there are many misconceptions and myths about this often hidden population. Older people misuse alcohol, nicotine, prescription medication and illicit drugs. ⋯ Patients present to a very wide variety of social and medical care settings, so screening and assessment for substance use are of paramount importance. This provides the opportunity to determine to what extent the substance problem is related to the presentation, which may be subtle and atypical in older people. Since evidence is accumulating of the benefit of treatment for substance problems in the older population, this group should not be marginalised and neglected by practitioners, researchers, educators and policy makers.
-
A working definition of personalised medicine is the delivery of a tailor-made treatment to the right patient at the right time. How close have recent advances in genetics come to realising this in the clinic?
-
The mechanisms that drive non-alcoholic fatty liver disease (NAFLD) progression from simple steatosis to non-alcoholic steatohepatitis (NASH) and NASH-fibrosis and/or cirrhosis are complex. Recent studies suggest that the liver progenitor cell (ie liver stem cell) population expands during chronic liver injury, and is an essential component of the repair process. Hedgehog (Hh) is a developmental morphogen that has an important role in the adult tissue repair (and progenitor) response. ⋯ Finally, the administration of Hh inhibitors led to reduced fibrosis in a model of NASH. Future studies are needed to evaluate the utility of these inhibitors in other models of chronic liver disease. If successful, this could pave the way for the development of new therapy for patients with NASH, because Hh pathway inhibitors have now been licensed for use in patients with advanced basal cell carcinoma.